Kolistimetatnatrium Accord

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Accord, is a Polymyxin presented as a sterile injectable solution for intracerebroventricular and intrathecal use. It treats severe infections caused by susceptible Gram‑negative bacteria and central nervous system infections such as meningitis and ventriculitis.

GNH USA supplies Kolistimetatnatrium Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Colistimethate Sodium is employed for serious Gram‑negative bacterial infections and central nervous system infections that require direct ventricular or spinal administration.

- Severe Gram‑negative bacterial infections: Provides bactericidal activity against susceptible strains in systemic or localized infections. - Bacterial meningitis: Delivers high concentrations of colistin directly to the cerebrospinal fluid to eradicate pathogens. - Ventriculitis: Allows targeted treatment of infection within the ventricular system when systemic therapy is insufficient.

Colistimethate Sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: Mild gastrointestinal discomfort reported in some patients. - Diarrhea: Loose stools occurring during therapy. - Injection site pain: Local discomfort at the administration site. - Transient fever: Low‑grade temperature rise.

Serious or Rare Side Effects: - Nephrotoxicity: Potential kidney injury requiring monitoring of renal function. - Neurotoxicity: Symptoms such as paresthesia, dizziness, or seizures. - Respiratory muscle weakness: May exacerbate breathing difficulties. - Anaphylaxis: Rare severe allergic reaction requiring immediate medical attention.

Colistimethate Sodium requires careful monitoring and adherence to safety guidelines.

- Renal function monitoring: Assess serum creatinine and urine output regularly. - Neurological assessment: Observe for signs of neurotoxicity, especially in patients receiving concomitant neurotoxic drugs. - Dose adjustment: Modify dosage in patients with impaired kidney function. - Concomitant nephrotoxic agents: Avoid or closely monitor when used with other kidney‑toxic medications. - Pregnancy and lactation: Use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze, and maintain the original packaging.

Colistimethate Sodium can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Neuromuscular blocking agents: May potentiate respiratory muscle weakness. - Aminoglycosides: Combined use increases risk of nephrotoxicity and ototoxicity. - Loop diuretics: Heightened potential for kidney injury.

Moderate Interactions (Monitor Closely): - Vancomycin: May increase nephrotoxic risk; monitor renal parameters. - Rifampicin: Can reduce colistin plasma concentrations; consider therapeutic drug monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May add to renal stress; observe kidney function.